Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-Intron vs Colchicine in Advanced HCV Fibrosis/Cirrhosis (COPILOT)
NCT00179413Phase 4Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jan 2000
- Primary completion
- Dec 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) and Liver cirrhosis (LC), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Time to Clinical Event (Hepatic Decompensation, HCC, Death, Transplant, Variceal Bleeding) at 4 years. Started Jan 2000; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT00179413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179413.